{"protocolSection":{"identificationModule":{"nctId":"NCT05070546","orgStudyIdInfo":{"id":"CR109038"},"secondaryIdInfos":[{"id":"2021-001909-77","type":"EUDRACT_NUMBER"},{"id":"VAC18193RSV3006","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."}],"organization":{"fullName":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"briefTitle":"A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-09-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-08-12","type":"ACTUAL"},"completionDateStruct":{"date":"2022-08-12","type":"ACTUAL"},"studyFirstSubmitDate":"2021-09-27","studyFirstSubmitQcDate":"2021-09-27","studyFirstPostDateStruct":{"date":"2021-10-07","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-08-11","resultsFirstSubmitQcDate":"2023-10-03","resultsFirstPostDateStruct":{"date":"2023-10-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-22","lastUpdatePostDateStruct":{"date":"2025-05-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF based vaccine in adults 18 to 59 years of age who are healthy or at risk for severe Respiratory Syncytial Virus (RSV) disease, compared to adults 65 years and above.","detailedDescription":"RSV is an important cause of serious respiratory infections in adults aged 60 years and older, immunocompromised individuals, and those with underlying chronic cardiopulmonary conditions. The current study assess the safety and immunogenicity of the RSV vaccine in adults 18 to 59 years of age, including those who are at risk for severe RSV disease. The study comprises screening (pre-vaccination) and vaccination for each participant on Day 1, and a 6- month safety and immunogenicity follow-up period. The study duration will be up to 6 months per participant. Assessments like immunogenicity (such as humoral and cellular immune responses), safety (such as monitoring of AEs, physical examinations, and vital signs) and reactogenicity will be performed in this study."},"conditionsModule":{"conditions":["Respiratory Syncytial Virus Infection Prevention"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":1124,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort (C)1 Group (G)1: Healthy Adults, 18-59 Years (Respiratory Syncytial Virus [RSV] vaccine)","type":"EXPERIMENTAL","description":"Participants will receive a single intramuscular (IM) injection of study vaccine on Day 1.","interventionNames":["Biological: Ad26.RSV.preF-based Vaccine"]},{"label":"C1 G2: Healthy Adults, 18-59 Years (Placebo)","type":"PLACEBO_COMPARATOR","description":"Participants will receive a single IM injection of matching placebo on Day 1.","interventionNames":["Other: Placebo"]},{"label":"C2 G3: High Risk Adult, 18-59 Years (RSV Vaccine)","type":"EXPERIMENTAL","description":"Participants will receive a single IM injection of study vaccine on Day 1.","interventionNames":["Biological: Ad26.RSV.preF-based Vaccine"]},{"label":"C2 G4: High Risk Adult, 18-59 Years (Placebo)","type":"PLACEBO_COMPARATOR","description":"Participants will receive a single IM injection of matching placebo on Day 1.","interventionNames":["Other: Placebo"]},{"label":"C3 G5: Adults, 65 Years and Older (RSV Vaccine)","type":"EXPERIMENTAL","description":"Participants will receive a single IM injection of study vaccine on Day 1.","interventionNames":["Biological: Ad26.RSV.preF-based Vaccine"]},{"label":"C3 G6: Adults, 65 Years and Older (Placebo)","type":"PLACEBO_COMPARATOR","description":"Participants will receive a single IM injection of matching placebo on Day 1.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.RSV.preF-based Vaccine","description":"Participants will receive a single IM injection of an RSV vaccine.","armGroupLabels":["C2 G3: High Risk Adult, 18-59 Years (RSV Vaccine)","C3 G5: Adults, 65 Years and Older (RSV Vaccine)","Cohort (C)1 Group (G)1: Healthy Adults, 18-59 Years (Respiratory Syncytial Virus [RSV] vaccine)"]},{"type":"OTHER","name":"Placebo","description":"Participants will receive a single IM injection of matching placebo.","armGroupLabels":["C1 G2: Healthy Adults, 18-59 Years (Placebo)","C2 G4: High Risk Adult, 18-59 Years (Placebo)","C3 G6: Adults, 65 Years and Older (Placebo)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Cohorts 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs)","description":"Number of participants with solicited local AEs at 7 days post-vaccination in Cohorts 1 and 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs were predefined local events (at the injection site: erythema, pain/tenderness and swelling) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination.","timeFrame":"7 days after vaccination on Day 1 (Day 8)"},{"measure":"Cohorts 1 and 2: Number of Participants With Solicited Systemic AEs","description":"Number of participants with solicited systemic AEs at 7 days post-vaccination in Cohorts 1 and 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited systemic AEs including pyrexia, headache, fatigue, myalgia and nausea were collected within 7 days after vaccination.","timeFrame":"7 days after vaccination on Day 1 (Day 8)"},{"measure":"Cohorts 1 and 2: Number of Participants With Unsolicited AEs","description":"Number of participants with unsolicited AEs post-vaccination in Cohorts 1 and 2 were reported. An AE was defined as any untoward medical occurrence in a participant participating in a clinical study that did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs were defined as all AEs for which the participant was not specifically questioned in the participant diary.","timeFrame":"28 days after vaccination on Day 1 (Day 29)"},{"measure":"Cohorts 1, 2, and 3: Number of Participants With Serious Adverse Events (SAEs)","description":"Number of participants with SAEs post-vaccination were reported. An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. SAE was defined as any AE that resulted in: death, persistent or significant disability/incapacity, required inpatient hospitalization or prolongation of existing hospitalization, was life-threatening experience, was a congenital anomaly/birth defect and would jeopardize participant and/or required medical or surgical intervention to prevent one of the outcomes listed above.","timeFrame":"6 months after vaccination on Day 1 (Day 183)"},{"measure":"Cohorts 1, 2, and 3: Number of Participants With Adverse Events of Special Interest (AESI)","description":"Number of participants with AESI post-vaccination were reported. AESIs were significant AEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Thrombosis with thrombocytopenia syndrome (TTS) was considered as an AESI.","timeFrame":"6 months after vaccination on Day 1 (Day 183)"},{"measure":"Cohorts 1 (Group 1), 2 (Group 3), and 3 (Group 5): Respiratory Syncytial Virus (RSV) A2 Strain Neutralizing Antibody Titers","description":"RSV A2 strain neutralizing antibody titers of the vaccine-induced immune response was assessed through virus neutralization assay and were expressed as 50% inhibitory concentration (IC50) units.","timeFrame":"14 days after vaccination on Day 1 (Day 15)"},{"measure":"Cohorts 1 (Group 1), 2 (Group 3), and 3 (Group 5): Percentage of Participants With Seroresponse as Assessed by Virus Neutralizing Assay (VNA-A2)","description":"Percentage of participants with seroresponse as assessed by VNA-A2 strain were reported. Seroresponse was defined as a 4-fold increase from baseline in Day 15 VNA A2 antibody titers.","timeFrame":"14 days after vaccination on Day 1 (Day 15)"}],"secondaryOutcomes":[{"measure":"Cohorts 1, 2, and 3: Geomteric Mean Titers (GMTs) of RSV Fusion Protein (F-protein) Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)- Pre-Fusion","description":"GMTs of RSV Fusion Protein (PreF) antibodies as assessed by ELISA-Pre-Fusion at Day 15 were reported.","timeFrame":"14 days after vaccination on Day 1 (Day 15)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must be of a) non child bearing potential or b) of child bearing potential and practicing an acceptable and effective of contraception\n* All participants of childbearing potential must: have a negative highly sensitive urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening; and have a negative highly sensitive urine beta-hCG pregnancy test immediately prior to each study vaccination (if screening and vaccination are not performed on the same day) Cohorts 1 and 2\n* Participant is aged 18 to 59 years (inclusive) on the day of signing the informed consent form (ICF) and expected to be available for the duration of the study Cohort 2\n* Has an existing chronic heart or lung condition, without hospitalizations or major medication class change (that is, new or stopped medications) within 30 days prior to screening, meeting the following criteria; a) cardiac disease: at least Class II symptoms per New York Heart Association classification or similar guidelines according to local practice, b) pulmonary disease: activity-restricting symptoms or use of long-term medications Cohort 3\n* Participant is aged 65 years or older on the day of signing the ICF and expected to be available for the duration of the study\n* Participant may have underlying illnesses such as hypertension, congestive heart failure, chronic obstructive pulmonary disease (COPD), type 2 diabetes, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms and signs are stable at the time of vaccination, and these conditions receive routine follow-up by the participant's healthcare provider\n\nExclusion Criteria:\n\n* Known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine)\n* Abnormal function of immune system due to a clinical condition or treatment\n* History of thrombosis with thrombocytopenia syndrome (TTS) or heparin-induced thrombocytopenia and thrombosis (HITT).\n* Participant received or plans to receive: (a) licensed live attenuated vaccines - within 28 days before or after planned administration of study vaccine; and (b) other licensed (not live) vaccines - within 14 days before or after planned administration of study vaccine\n* Received an respiratory syncytial virus (RSV) vaccine in a previous RSV vaccine study\n* History of acute polyneuropathy (example, Guillain-Barre syndrome) or chronic idiopathic demyelinating polyneuropathy","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Vaccines & Prevention B.V. Clinical Trial","affiliation":"Janssen Vaccines & Prevention B.V.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Alliance for Multispeciality Research","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"Research Institute of South Florida Inc","city":"Miami","state":"Florida","zip":"33173","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Heartland Research Associates, an AMR Company","city":"El Dorado","state":"Kansas","zip":"67042","country":"United States","geoPoint":{"lat":37.81724,"lon":-96.86225}},{"facility":"AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company","city":"New Orleans","state":"Louisiana","zip":"70119","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Meridian Clinical Research, LLC","city":"Rockville","state":"Maryland","zip":"20854","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Tekton Research Inc.","city":"Yukon","state":"Oklahoma","zip":"73099","country":"United States","geoPoint":{"lat":35.50672,"lon":-97.76254}},{"facility":"Alliance for Multispeciality Research","city":"Knoxville","state":"Tennessee","zip":"37909","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Anima","city":"Alken","zip":"3570","country":"Belgium","geoPoint":{"lat":50.87553,"lon":5.30558}},{"facility":"C.H.U. St Pierre / Maladies Infectieuses","city":"Brussels","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Private Practice RESPISOM Namur","city":"Namur","zip":"5101","country":"Belgium","geoPoint":{"lat":50.4669,"lon":4.86746}},{"facility":"Emovis GmbH","city":"Berlin","zip":"10629","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Klinische Forschung Berlin GbR","city":"Berlin","zip":"10787","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Zentrum fuer klinische Forschung","city":"Cologne","zip":"51069","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Klinische Forschung Dresden GmbH","city":"Dresden","zip":"01069","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"Clinical Research HamburggmbH","city":"Hamburg","zip":"22143","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"SIBAmed GmbH & Co. KG","city":"Leipzig","zip":"04103","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Klinische Forschung Schwerin GmbH","city":"Schwerin","zip":"19055","country":"Germany","geoPoint":{"lat":53.62937,"lon":11.41316}},{"facility":"Hosp Reina Sofia","city":"Córdoba","zip":"14004","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"facility":"Hosp Virgen de La Victoria","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"ProbarE i Lund AB","city":"Lund","zip":"22222","country":"Sweden","geoPoint":{"lat":55.70584,"lon":13.19321}},{"facility":"ClinSmart Sweden AB","city":"Solna","zip":"171 64","country":"Sweden","geoPoint":{"lat":59.36004,"lon":18.00086}},{"facility":"ProbarE i Stockholm AB","city":"Stockholm","zip":"113 29","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"Studieenheten Akademiskt Specialistcentrum Stockholm","city":"Stockholm","zip":"11361","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}}]},"referencesModule":{"references":[{"pmid":"39971605","type":"DERIVED","citation":"LaRoche JK, Lanier J, Alvarenga R, Collins M, Costelloe T, Chiau A, Whetherly H, De Soete W, Faludi J, Rens K. Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas. BMJ Open. 2025 Feb 19;15(2):e085364. doi: 10.1136/bmjopen-2024-085364."},{"pmid":"39536455","type":"DERIVED","citation":"Jastorff A, Gymnopoulou E, Salas J, Merrall E, Buntinx E, Martin C, Askling HH, Schenkenberger I, Yuste AC, Smith W, Sotolongo R, Von Engelhardt C, Bastian AR, Comeaux C, Ligtenberg N, Callendret B, Heijnen E. Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial. Vaccine. 2025 Jan 1;43(Pt 1):126514. doi: 10.1016/j.vaccine.2024.126514. Epub 2024 Nov 12."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu","url":"https://www.janssen.com/clinical-trials/transparency"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein","description":"Healthy adult participants aged 18 to 59 years received a single intramuscular (IM) injection containing mixture of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) on Day 1."},{"id":"FG001","title":"Group 2 (Cohort 1): Placebo","description":"Healthy adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"FG002","title":"Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","description":"High-risk adult participants aged 18 to 59 years received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"FG003","title":"Group 4 (Cohort 2): Placebo","description":"High-risk adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"FG004","title":"Group 5 (Cohort 3): Ad26.RSV.preF and RSV preF Protein","description":"Adult participants aged 65 years and older received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"FG005","title":"Group 6 (Cohort 3): Placebo","description":"Adult participants aged 65 years and older received a single IM injection of matching placebo on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"320"},{"groupId":"FG001","numSubjects":"68"},{"groupId":"FG002","numSubjects":"320"},{"groupId":"FG003","numSubjects":"70"},{"groupId":"FG004","numSubjects":"316"},{"groupId":"FG005","numSubjects":"30"}]},{"type":"Vaccinated","achievements":[{"groupId":"FG000","numSubjects":"319"},{"groupId":"FG001","numSubjects":"68"},{"groupId":"FG002","numSubjects":"319"},{"groupId":"FG003","numSubjects":"69"},{"groupId":"FG004","numSubjects":"313"},{"groupId":"FG005","numSubjects":"30"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"310"},{"groupId":"FG001","numSubjects":"65"},{"groupId":"FG002","numSubjects":"309"},{"groupId":"FG003","numSubjects":"68"},{"groupId":"FG004","numSubjects":"308"},{"groupId":"FG005","numSubjects":"29"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Randomized but not vaccinated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set (FAS) included all participants who received study vaccine, regardless of the occurrence of protocol deviations and vaccine type (study vaccine or placebo).","groups":[{"id":"BG000","title":"Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein","description":"Healthy adult participants aged 18 to 59 years received a single intramuscular (IM) injection containing mixture of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) on Day 1."},{"id":"BG001","title":"Group 2 (Cohort 1): Placebo","description":"Healthy adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"BG002","title":"Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","description":"High-risk adult participants aged 18 to 59 years received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"BG003","title":"Group 4 (Cohort 2): Placebo","description":"High-risk adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"BG004","title":"Group 5 (Cohort 3): Ad26.RSV.preF and RSV preF Protein","description":"Adult participants aged 65 years and older received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"BG005","title":"Group 6 (Cohort 3): Placebo","description":"Adult participants aged 65 years and older received a single IM injection of matching placebo on Day 1."},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"319"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"319"},{"groupId":"BG003","value":"69"},{"groupId":"BG004","value":"313"},{"groupId":"BG005","value":"30"},{"groupId":"BG006","value":"1118"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"38.8","spread":"12.33"},{"groupId":"BG001","value":"38.4","spread":"12.34"},{"groupId":"BG002","value":"44.4","spread":"11.81"},{"groupId":"BG003","value":"44.6","spread":"11.58"},{"groupId":"BG004","value":"71.1","spread":"4.74"},{"groupId":"BG005","value":"71.2","spread":"5.1"},{"groupId":"BG006","value":"50.6","spread":"17.27"}]}]}]},{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Adults (18-64 years)","measurements":[{"groupId":"BG000","value":"319"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"319"},{"groupId":"BG003","value":"69"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"775"}]},{"title":"From 65 and over","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"313"},{"groupId":"BG005","value":"30"},{"groupId":"BG006","value":"343"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"193"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"174"},{"groupId":"BG003","value":"39"},{"groupId":"BG004","value":"181"},{"groupId":"BG005","value":"21"},{"groupId":"BG006","value":"648"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"145"},{"groupId":"BG003","value":"30"},{"groupId":"BG004","value":"132"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"470"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"19"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"122"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"274"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"276"},{"groupId":"BG003","value":"60"},{"groupId":"BG004","value":"289"},{"groupId":"BG005","value":"28"},{"groupId":"BG006","value":"984"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"12"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"3"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"45"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"289"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"308"},{"groupId":"BG003","value":"68"},{"groupId":"BG004","value":"303"},{"groupId":"BG005","value":"29"},{"groupId":"BG006","value":"1061"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"5"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"BELGIUM","categories":[{"measurements":[{"groupId":"BG000","value":"178"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"18"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"278"}]}]},{"title":"GERMANY","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"175"},{"groupId":"BG003","value":"38"},{"groupId":"BG004","value":"88"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"312"}]}]},{"title":"SPAIN","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"20"}]}]},{"title":"SWEDEN","categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"160"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"277"}]}]},{"title":"UNITED STATES","categories":[{"measurements":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"41"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"47"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"231"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Cohorts 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs)","description":"Number of participants with solicited local AEs at 7 days post-vaccination in Cohorts 1 and 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs were predefined local events (at the injection site: erythema, pain/tenderness and swelling) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination.","populationDescription":"Full analysis set (FAS) included all participants who received study vaccine, regardless of the occurrence of protocol deviations and vaccine type (study vaccine or placebo). Here 'N' (number of participants analysed) signifies number of participants who were evaluable for this outcome measure. This outcome measure was planned to be analysed for specified cohorts only.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days after vaccination on Day 1 (Day 8)","groups":[{"id":"OG000","title":"Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein","description":"Healthy adult participants aged 18 to 59 years received a single intramuscular (IM) injection containing mixture of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) on Day 1."},{"id":"OG001","title":"Group 2 (Cohort 1): Placebo","description":"Healthy adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"OG002","title":"Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","description":"High-risk adult participants aged 18 to 59 years received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"OG003","title":"Group 4 (Cohort 2): Placebo","description":"High-risk adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"318"},{"groupId":"OG003","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"276"},{"groupId":"OG003","value":"15"}]}]}]},{"type":"PRIMARY","title":"Cohorts 1 and 2: Number of Participants With Solicited Systemic AEs","description":"Number of participants with solicited systemic AEs at 7 days post-vaccination in Cohorts 1 and 2 were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited systemic AEs including pyrexia, headache, fatigue, myalgia and nausea were collected within 7 days after vaccination.","populationDescription":"FAS included all participants who received study vaccine, regardless of the occurrence of protocol deviations and vaccine type (study vaccine or placebo). Here 'N' (number of participants analysed) signifies number of participants who were evaluable for this outcome measure. This outcome measure was planned to be analysed for specified cohorts only.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days after vaccination on Day 1 (Day 8)","groups":[{"id":"OG000","title":"Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein","description":"Healthy adult participants aged 18 to 59 years received a single intramuscular (IM) injection containing mixture of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) on Day 1."},{"id":"OG001","title":"Group 2 (Cohort 1): Placebo","description":"Healthy adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"OG002","title":"Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","description":"High-risk adult participants aged 18 to 59 years received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"OG003","title":"Group 4 (Cohort 2): Placebo","description":"High-risk adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"318"},{"groupId":"OG003","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"275"},{"groupId":"OG003","value":"40"}]}]}]},{"type":"PRIMARY","title":"Cohorts 1 and 2: Number of Participants With Unsolicited AEs","description":"Number of participants with unsolicited AEs post-vaccination in Cohorts 1 and 2 were reported. An AE was defined as any untoward medical occurrence in a participant participating in a clinical study that did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs were defined as all AEs for which the participant was not specifically questioned in the participant diary.","populationDescription":"FAS included all participants who received study vaccine, regardless of the occurrence of protocol deviations and vaccine type (study vaccine or placebo). This outcome measure was planned to be analysed for specified cohorts only.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"28 days after vaccination on Day 1 (Day 29)","groups":[{"id":"OG000","title":"Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein","description":"Healthy adult participants aged 18 to 59 years received a single intramuscular (IM) injection containing mixture of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) on Day 1."},{"id":"OG001","title":"Group 2 (Cohort 1): Placebo","description":"Healthy adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"OG002","title":"Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","description":"High-risk adult participants aged 18 to 59 years received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"OG003","title":"Group 4 (Cohort 2): Placebo","description":"High-risk adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"319"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"319"},{"groupId":"OG003","value":"69"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"12"}]}]}]},{"type":"PRIMARY","title":"Cohorts 1, 2, and 3: Number of Participants With Serious Adverse Events (SAEs)","description":"Number of participants with SAEs post-vaccination were reported. An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. SAE was defined as any AE that resulted in: death, persistent or significant disability/incapacity, required inpatient hospitalization or prolongation of existing hospitalization, was life-threatening experience, was a congenital anomaly/birth defect and would jeopardize participant and/or required medical or surgical intervention to prevent one of the outcomes listed above.","populationDescription":"FAS included all participants who received study vaccine, regardless of the occurrence of protocol deviations and vaccine type (study vaccine or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"6 months after vaccination on Day 1 (Day 183)","groups":[{"id":"OG000","title":"Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein","description":"Healthy adult participants aged 18 to 59 years received a single intramuscular (IM) injection containing mixture of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) on Day 1."},{"id":"OG001","title":"Group 2 (Cohort 1): Placebo","description":"Healthy adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"OG002","title":"Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","description":"High-risk adult participants aged 18 to 59 years received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"OG003","title":"Group 4 (Cohort 2): Placebo","description":"High-risk adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"OG004","title":"Group 5 (Cohort 3): Ad26.RSV.preF and RSV preF Protein","description":"Adult participants aged 65 years and older received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"OG005","title":"Group 6 (Cohort 3): Placebo","description":"Adult participants aged 65 years and older received a single IM injection of matching placebo on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"319"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"319"},{"groupId":"OG003","value":"69"},{"groupId":"OG004","value":"313"},{"groupId":"OG005","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"1"}]}]}]},{"type":"PRIMARY","title":"Cohorts 1, 2, and 3: Number of Participants With Adverse Events of Special Interest (AESI)","description":"Number of participants with AESI post-vaccination were reported. AESIs were significant AEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Thrombosis with thrombocytopenia syndrome (TTS) was considered as an AESI.","populationDescription":"FAS included all participants who received study vaccine, regardless of the occurrence of protocol deviations and vaccine type (study vaccine or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"6 months after vaccination on Day 1 (Day 183)","groups":[{"id":"OG000","title":"Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein","description":"Healthy adult participants aged 18 to 59 years received a single intramuscular (IM) injection containing mixture of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) on Day 1."},{"id":"OG001","title":"Group 2 (Cohort 1): Placebo","description":"Healthy adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"OG002","title":"Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","description":"High-risk adult participants aged 18 to 59 years received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"OG003","title":"Group 4 (Cohort 2): Placebo","description":"High-risk adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"OG004","title":"Group 5 (Cohort 3): Ad26.RSV.preF and RSV preF Protein","description":"Adult participants aged 65 years and older received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"OG005","title":"Group 6 (Cohort 3): Placebo","description":"Adult participants aged 65 years and older received a single IM injection of matching placebo on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"319"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"319"},{"groupId":"OG003","value":"69"},{"groupId":"OG004","value":"313"},{"groupId":"OG005","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Cohorts 1 (Group 1), 2 (Group 3), and 3 (Group 5): Respiratory Syncytial Virus (RSV) A2 Strain Neutralizing Antibody Titers","description":"RSV A2 strain neutralizing antibody titers of the vaccine-induced immune response was assessed through virus neutralization assay and were expressed as 50% inhibitory concentration (IC50) units.","populationDescription":"The Per-protocol Immunogenicity (PPI) set included all randomised participants on Day 15 who received study vaccine and for whom immunogenicity data were available. Here 'N' (number of participants analysed) signifies number of participants who were evaluable for this outcome measure. This outcome measure was planned to be analysed for specified arms only. As planned, combined data of participants aged 18-59 years Cohorts 1 (Group 1) and 2 (Group 3) has been reported.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"14 days after vaccination on Day 1 (Day 15)","groups":[{"id":"OG000","title":"Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","description":"High-risk adult participants aged 18 to 59 years received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"OG001","title":"Group 5 (Cohort 3): Ad26.RSV.preF and RSV preF Protein","description":"Adult participants aged 65 years and older received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"OG002","title":"Group 1 (Cohort 1) and Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","description":"Healthy (Group 1) and high-risk adult (Group 3) participants aged 18 to 59 years received intramuscular (IM) injection containing mixture of adenovirus serotype 26 pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and respiratory syncytial virus prefusion F-protein (RSV preF protein) 150 micrograms (mcg) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"290"},{"groupId":"OG002","value":"602"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7095","lowerLimit":"6261","upperLimit":"8042"},{"groupId":"OG001","value":"4596","lowerLimit":"4059","upperLimit":"5204"},{"groupId":"OG002","value":"6491","lowerLimit":"5847","upperLimit":"7206"}]}]}],"analyses":[{"groupIds":["OG001","OG002"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority of Cohort 3 (Group 5) versus Cohorts 1 (Group 1) and 2 (Group 3) in terms of RSV A2 Strain neutralizing antibody titers against 14 days after vaccination, using a non-inferiority margin of 0.67 for the GMT ratio (Cohort 3 \\[Group 5\\]/Cohort 1\\[Group1\\] and 2 \\[Group 3\\])","statisticalMethod":"Geometric Mean Ratio","paramType":"Geometric Mean Ratio","paramValue":"1.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.25","ciUpperLimit":"1.60"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority of Cohort 3 (Group 5) versus Cohort 2 (Group 3 in terms of RSV A2 Strain neutralizing antibody titers against 14 days after vaccination, using a non-inferiority margin of 0.67 for the GMT ratio (Cohort 3 \\[Group 5\\]/Cohort 2 \\[Group 3\\])","statisticalMethod":"Geometric Mean Ratio","paramType":"Geometric mean ratio","paramValue":"1.54","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.34","ciUpperLimit":"1.78"}]},{"type":"PRIMARY","title":"Cohorts 1 (Group 1), 2 (Group 3), and 3 (Group 5): Percentage of Participants With Seroresponse as Assessed by Virus Neutralizing Assay (VNA-A2)","description":"Percentage of participants with seroresponse as assessed by VNA-A2 strain were reported. Seroresponse was defined as a 4-fold increase from baseline in Day 15 VNA A2 antibody titers.","populationDescription":"PPI set included all randomized participants who received study vaccine and for whom immunogenicity data were available. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. This outcome measure was planned to be analysed for specified arms only. As planned, combined data of participants aged 18-59 years Cohorts 1 (Group 1) and 2 (Group 3) has been reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"14 days after vaccination on Day 1 (Day 15)","groups":[{"id":"OG000","title":"Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","description":"High-risk adult participants aged 18 to 59 years received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"OG001","title":"Group 5 (Cohort 3): Ad26.RSV.preF and RSV preF Protein","description":"Adult participants aged 65 years and older received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"OG002","title":"Cohorts 1(Group 1) and 2 (Group 3): Ad26.RSV.preF and RSV preF Protein","description":"Healthy (Group 1) and high-risk adult (Group 3) participants aged 18 to 59 years received intramuscular (IM) injection containing mixture of adenovirus serotype 26 pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and respiratory syncytial virus prefusion F-protein (RSV preF protein) 150 micrograms (mcg) on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"290"},{"groupId":"OG002","value":"602"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"82.41"},{"groupId":"OG002","value":"89.37"}]}]}],"analyses":[{"groupIds":["OG001","OG002"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority of Cohort 3 (Group 5) versus Cohorts 1 (Group 1) and 2 (Group 3) in terms of RSV A2 Strain neutralizing antibody titers against 14 days after vaccination, using a non-inferiority margin of -10% for the GMT ratio (Cohort 3 \\[Group 5\\]/Cohort 1\\[Group1\\] and 2 \\[Group 3\\]).","statisticalMethod":"Difference in Seroresponse rate","paramType":"Difference in Seroresponse rate","paramValue":"5.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.3","ciUpperLimit":"10.9"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Non-inferiority of Cohort 3 (Group 5) versus Cohorts 1 (Group 1) and 2 (Group 3) in terms of RSV A2 Strain neutralizing antibody titers against 14 days after vaccination, using a non-inferiority margin of -10% for the GMT ratio (Cohort 3 \\[Group 5\\]/Cohort 2 \\[Group 3\\]).","statisticalMethod":"Difference in Seroresponse rate","paramType":"Difference in Seroresponse rate","paramValue":"4.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.6","ciUpperLimit":"10.5"}]},{"type":"SECONDARY","title":"Cohorts 1, 2, and 3: Geomteric Mean Titers (GMTs) of RSV Fusion Protein (F-protein) Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)- Pre-Fusion","description":"GMTs of RSV Fusion Protein (PreF) antibodies as assessed by ELISA-Pre-Fusion at Day 15 were reported.","populationDescription":"PPI set included all randomised participants who received study vaccine and for whom immunogenicity data were available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ELISA units per liter (EU/L)","timeFrame":"14 days after vaccination on Day 1 (Day 15)","groups":[{"id":"OG000","title":"Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein","description":"Healthy adult participants aged 18 to 59 years received a single intramuscular (IM) injection containing mixture of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) on Day 1."},{"id":"OG001","title":"Group 2 (Cohort 1): Placebo","description":"Healthy adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"OG002","title":"Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","description":"High-risk adult participants aged 18 to 59 years received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1."},{"id":"OG003","title":"Group 4 (Cohort 2): Placebo","description":"High-risk adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1."},{"id":"OG004","title":"Cohort 3: Adults: RSV Vx (Group 5)","description":"Adult participants aged 65 years and older received IM injection containing Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1 of vaccination."},{"id":"OG005","title":"Group 6 (Cohort 3): Placebo","description":"Adult participants aged 65 years and older received a single IM injection of matching placebo on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"302"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"301"},{"groupId":"OG003","value":"61"},{"groupId":"OG004","value":"290"},{"groupId":"OG005","value":"29"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4662","lowerLimit":"4350","upperLimit":"4997"},{"groupId":"OG001","value":"246","lowerLimit":"214","upperLimit":"284"},{"groupId":"OG002","value":"5175","lowerLimit":"4808","upperLimit":"5569"},{"groupId":"OG003","value":"283","lowerLimit":"246","upperLimit":"326"},{"groupId":"OG004","value":"3864","lowerLimit":"3559","upperLimit":"4196"},{"groupId":"OG005","value":"240","lowerLimit":"203","upperLimit":"285"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"Up to Day 183","description":"Full analysis set included all participants who received study vaccine, regardless of the occurrence of protocol deviations and vaccine type (study vaccine or placebo).","eventGroups":[{"id":"EG000","title":"Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein","description":"Healthy adult participants aged 18 to 59 years received a single intramuscular (IM) injection containing mixture of adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation-stabilized F protein (Ad26.RSV.preF) 1\\*10\\^11 viral particles (vp) and RSV preF protein 150 micrograms (mcg) on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":319,"seriousNumAffected":1,"seriousNumAtRisk":319,"otherNumAffected":77,"otherNumAtRisk":319},{"id":"EG001","title":"Group 2 (Cohort 1): Placebo","description":"Healthy adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":68,"seriousNumAffected":1,"seriousNumAtRisk":68,"otherNumAffected":5,"otherNumAtRisk":68},{"id":"EG002","title":"Group 3 (Cohort 2): Ad26.RSV.preF and RSV preF Protein","description":"High-risk adult participants aged 18 to 59 years received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":319,"seriousNumAffected":10,"seriousNumAtRisk":319,"otherNumAffected":50,"otherNumAtRisk":319},{"id":"EG003","title":"Group 4 (Cohort 2): Placebo","description":"High-risk adult participants aged 18 to 59 years received a single IM injection of matching placebo on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":69,"seriousNumAffected":0,"seriousNumAtRisk":69,"otherNumAffected":8,"otherNumAtRisk":69},{"id":"EG004","title":"Group 5 (Cohort 3): Ad26.RSV.preF and RSV preF Protein","description":"Adult participants aged 65 years and older received a single IM injection containing mixture of Ad26.RSV.preF 1\\*10\\^11 vp and RSV preF protein 150 mcg on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":313,"seriousNumAffected":13,"seriousNumAtRisk":313,"otherNumAffected":32,"otherNumAtRisk":313},{"id":"EG005","title":"Group 6 (Cohort 3): Placebo","description":"Adult participants aged 65 years and older received a single IM injection of matching placebo on Day 1.","deathsNumAffected":1,"deathsNumAtRisk":30,"seriousNumAffected":1,"seriousNumAtRisk":30,"otherNumAffected":5,"otherNumAtRisk":30}],"seriousEvents":[{"term":"Angina Pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Aortic Valve Stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Cardiogenic Shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":30}]},{"term":"Coronary Artery Disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":30}]},{"term":"Gastroenteritis Viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Haemorrhagic Fever with Renal Syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Herpes Zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Mastitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":1,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Meningitis Aseptic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Radius Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Thermal Burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Traumatic Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Bladder Cancer Stage 0, with Cancer in Situ","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Her2 Positive Breast Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Facial Paresis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Testicular Torsion","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Chronic Obstructive Pulmonary Disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Hypertensive Crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]}],"otherEvents":[{"term":"Ear Pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":0,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":30}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":319},{"groupId":"EG001","numAffected":1,"numAtRisk":68},{"groupId":"EG002","numAffected":2,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":30}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":2,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":60,"numAtRisk":319},{"groupId":"EG001","numAffected":1,"numAtRisk":68},{"groupId":"EG002","numAffected":31,"numAtRisk":319},{"groupId":"EG003","numAffected":1,"numAtRisk":69},{"groupId":"EG004","numAffected":15,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":319},{"groupId":"EG001","numAffected":1,"numAtRisk":68},{"groupId":"EG002","numAffected":4,"numAtRisk":319},{"groupId":"EG003","numAffected":3,"numAtRisk":69},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":30}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":9,"numAtRisk":319},{"groupId":"EG003","numAffected":3,"numAtRisk":69},{"groupId":"EG004","numAffected":9,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":30}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":30}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":3,"numAtRisk":69},{"groupId":"EG004","numAffected":1,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":30}]},{"term":"Muscle Spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":1,"numAtRisk":30}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":319},{"groupId":"EG001","numAffected":4,"numAtRisk":68},{"groupId":"EG002","numAffected":2,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":2,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]},{"term":"Night Sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":319},{"groupId":"EG001","numAffected":0,"numAtRisk":68},{"groupId":"EG002","numAffected":1,"numAtRisk":319},{"groupId":"EG003","numAffected":0,"numAtRisk":69},{"groupId":"EG004","numAffected":0,"numAtRisk":313},{"groupId":"EG005","numAffected":0,"numAtRisk":30}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application."},"pointOfContact":{"title":"Director Biomarkers Viral Vaccines","organization":"Janssen Vaccines & Prevention B.V.","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-11-30","uploadDate":"2023-08-11T06:35","filename":"Prot_000.pdf","size":1683640},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-07-11","uploadDate":"2023-08-11T06:35","filename":"SAP_001.pdf","size":870999}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-09-11","type":"ACTUAL"}}}}},"hasResults":true}